{
  "id": 1507818,
  "title": "AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer",
  "url": "https://urgent.news/2026/08/17/astrazeneca-scraps-phase-3-trial-of-new-bispecific-in-lung-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T15:13:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/astrazeneca-discontinues-trial-volrustomig-lung-cancer/827999/"
  },
  "original_language": "en",
  "account": null,
  "summary": "An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the U.K. company is leaning on to meet an $80 billion sales goal.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer",
        "url": "https://urgent.news/2026/08/17/astrazenecas-tagrisso-plus-orpathys-extends-survival-in-lung-cancer",
        "published": "2026-08-17T06:25:05.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "AstraZeneca cans late-stage volrustomig trial after lung cancer setback",
        "url": "https://urgent.news/2026/08/17/astrazeneca-cans-late-stage-volrustomig-trial-after-lung-cancer",
        "published": "2026-08-17T10:47:39.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}